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Extramedullary hematopoiesisMyelolipoma is a rare neoplasm composed of mature fat and bone marrow occurring most frequently in the ad-
renal gland with rare occurrences in extra adrenal locations including lung, liver, retroperitoneum,mediastinum
and testes. Splenic myelolipomas are seen most commonly in non-human species including cat and dog. Only
rare cases of splenic myelolipoma in humans have been reported previously. We present two cases of
myelolipoma in the spleen. The ﬁrst is a 62 year old female presenting with abdominal pain and a splenic
mass. The second is a 44 year old male presenting with hematuria and a mass in the spleen. Both cases showed
trilineage bone marrow elements with mature fat. These cases demonstrate that myelolipoma do rarely occur in
human spleen andwe highlight the distinction from extramedullary hematopoiesis, mature extramedullarymy-
eloid tumor (myeloid sarcoma), lipoma and well differentiated liposarcoma.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Myelolipomas (ML) most commonly present as an adrenal mass oc-
casionally becoming hemorrhagic and rarely as an extra adrenal
myelolipoma (EAML). Adrenal myelolipoma are commonly asymptom-
atic butmay rupture and cause acute abdomennecessitating surgical in-
tervention [1]. A wide age range at presentation is seen in ML and there
is no sex predilection. They varywidely in sizewithmost being between
5 and 10 cm in diameter. EAML are usually incidental and require no
speciﬁc treatment. EAML is an extremely rare tumor presenting as a be-
nign fatty mass or containing both soft tissue and fat in radiologic stud-
ies [2]. EAMLs have been located in the pelvis [3], chest/mediastinum
[3,4], retroperitoneum [5], peri-renal [4], omentum [2], liver [3], nasal
cavity [6]and rarely spleen [7–9]Splenic myelolipomas are more com-
monly seen in other species including cat and dog [10,11], but rarely
in humans.2. Case report
Cases were sent as consultative cases to the Armed Forces Institute
of Pathology now Joint Pathology Center, Silver Spring MD. Hematoxy-
lin and eosin stained sections of each case were examined. Parafﬁn em-
bedded tissue was available for case 2 and immunohistochemistry was
performed. Immunohistochemical staining for CD61 (Immunotech,System, P.O. Box 800214, Char-
is is an open access article under the CCMiami, FL) and MDM2 (Novus Biologials, Littleton, CO), CD8 (DAKO,
Carpinteria CA), hemoglobin peroxidase (DAKO)were donewith an au-
tomated immunohistochemical staining system, DAKO Autostainer,
with antigen retrieval and antibody dilutions per manufacturer
recommendation.
2.1. Case 1
The patient was a 62 year old African American female presenting
with an abdominal pain. Imaging studies showed a 4.2 cm mass in the
right ascending colon and an 8.5 cm in the spleen. To evaluate both a
splenic mass and a colonic mass, the patient underwent a splenectomy
and segmental resection of the right large intestine. The spleenweighed
228 g. The gross ﬁndings showed a well circumscribed mass 8.5 cm in
greatest dimension. The splenic mass showed a yellow to reddish cut
surface (Fig. 1). Bone marrow elements with trilineage hematopoiesis
and normal fat were seen in the mass. Extensive hemorrhage was pres-
ent in themass and in the surrounding spleen. The right colonwas diag-
nosed with colonic adenocarcinoma and the splenic mass was
diagnosed as myelolipoma and considered incidental.
2.2. Case 2
The patient was a 44 year old male who presented with hematuria.
CT scan detected a large splenic mass which was displacing the kidney.
Grossly the spleen weighed 197 g. The mass was well deﬁned grossly.
Microscopically bone marrow elements showing trilineage hematopoi-
esis was presentwithmature fat (Fig. 2). Focal hemorrhagewas present
in themass. Immunohistochemistry showed no CD8 positive lining cellsBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A) Gross image of the uncut spleen showing a 8.5 CMmass in greatest dimension, B) Gross image of the cut surface of the mass showing a yellow-white surface and hemorrhagic
areas. Normal spleen can be seen at the periphery, C) 4XH&Eof case 1 showingmature fatwith surrounding splenic tissue showing hemorrhage. D) 40XH&E showing hematopoiesiswith
all three cell lines present with normal morphology.
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moglobin peroxidase marked clusters of erythroid cells.
Myeloperoxidase marked the myeloid cells and CD61 highlighted
scattered megakaryocytes. MDM2 staining was negative.
The splenic mass was diagnosed as a myelolipoma and the hematu-
ria resolved after splenectomy and was felt to be unrelated to the mass.
Neither case showed boney spicules or adrenal elements. No atypia
in the fat was seen in either case. Normal spleen was present at the pe-
riphery of themass in both cases and no extramedullary hematopoiesis
outside of the mass was seen.Fig. 2. A) 2X H&E image of case 2 mass showing bonemarrow elements and fat. B) 40X H&E im
mature fat.3. Discussion
Myelolipomas (ML) are tumors composed of mature bone marrow
elements withmature adipose tissue. Hematopoietic cells typically rep-
resent variable numbers of all 3 lineage of cells: myeloid cells, red cells
and megakaryocytes. There can be no contiguous areas with the bone
marrow. No bone spicules or sinuses are commonly present within
the tumor tissue, but rare cases show mature bone formation [1]. Al-
though outside the spleen they generally present as a single
circumscribed, non-encapsulated well-deﬁned mass, within the spleenage shows hematopoietic cells of myeloid, erythroid and megakaryocytic precursors with
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involve the surrounding spleen [12]. This ﬁrst report of a case of splenic
extra adrenal myelolipoma was described as showing “no uninvolved
splenic parenchyma” [7]; in the same case tissue resembling adrenal tis-
sue was also described [7]. Both of the present cases showed well
circumscribed splenic mass with normal splenic tissue at the periphery,
similar to two recent cases [8,9]. Rarely bone marrow suppression may
be seen with ML [4]. The clinical presentation of ML cases in the litera-
ture are reviewed in Table 1.
Splenic myelolipoma can be an incidental ﬁnding in a spleen re-
moved or biopsied for other reasons, but can also present as a symptom-
atic splenic mass. In both of our cases, imaging studies showed a splenic
mass. In patient 1, the patient had abdominal pain which was presum-
ably due to a concurrent colonic adenocarcinoma and the splenic mass
was most likely asymptomatic. On the other hand, the myelolipoma
may have caused the symptoms in patient 2, by compressing the kidney
resulting in hematuria although this could not be documented.
Amajor differential diagnosis in cases of EAML is extramedullary he-
matopoiesis (EMH), which is very common in the spleen. EMH is not as-
sociated with a mass in most cases although the spleen may be
markedly enlarged. EMH is often associated with an abnormality in
the bone marrow or peripheral blood or primary bone marrow process
andmay be a proliferation of the underlying neoplastic bonemarrow el-
ements. There has been discussion that other terms such as “neoplastic
myeloid proliferation” should be used in cases associated with myelo-
proliferative neoplasms rather than EMH [13]. Myeloid sarcoma (MS)
must also be considered in the differential. In our cases no immature
bonemarrow elementswere present andMS does not generally contain
fat. It is therefore important to exclude EMHandMSaswell as anunder-
lying myeloproliferative neoplasm particularly when EAML occurs in
the spleen.Table 1
Clinical presentations of reported splenic myelolipoma.
Case Author Age/sex Clinical Radio
1 [9] Zeng
Y et al.
(2015)
42y/M,
Chinese
One month history of abdominal pain CT dem
hetero
12.4X
liposa
2 [8] Wood
WG et al.
(2013)
64y/M,
Caucasian
Patient history positive for multiple abdominal
surgeries with new diagnosis of myasthenia gravis;
Pt evaluated for thymectomy which revealed an
incidental splenic mass but no thymoma.
CT dem
spleni
9 year
mass
3 [12]
Diebold J
et al.
(2013)
67y/F Fever and weight loss of unknown etiology.
Examination revealed splenomegaly
NR
4 [12]
Diebold J
et al.
(2013)
65y/F Chronic diarrhea of unknown etiology.
Examination revealed splenomegaly only
Ultras
tumor
5 [7] Cina
SJ et al.
(1995)
28y/F,
African
American
Homozygous sickle disease; cholelithiasis with
abdominal pain and vomiting; incidental
“retroperitoneal” mass
CT: in
“retro
areas
6 Aguilera
NS et al.
(present
report)
62y/F,
African
American
Presented with abdominal pain secondary to colon
carcinoma with incidental splenic mass
“Imag
mass
8.5 cm
7 Aguilera
NS et al.
(present
report)
44y/M Presented with hematuria; splenic mass likely
incidental
CT dem
displa
Abbreviations: y = years; g = grams; F = female; M = male; cm = centimeters; CT = com
reported.Since adipose tissue is a deﬁning component of myelolipomas, well
differentiated liposarcomas and lipomas are included in the differential
diagnosis. This differential occursmost commonly in imaging character-
isticswith pathology elucidating the ﬁnal diagnosis. Lipomas are benign
fatty tumors that are usually encapsulated and consist of aggregates of
fat. Lipomas do not have hematopoietic elements and thus our two
cases could not be diagnosed as lipomas. Well-differentiated
liposarcoma are fatty tumors that have scattered atypical cells with
hyperchromatic nuclei and can contain lipoblasts. Our two cases did
not show atypia or lipoblasts. Molecular testing for MDM2 is often pos-
itive in liposarcoma and can be used to separate well differentiated
liposarcoma from lipoma [14]. Our second case was MDM2 negative,
further distinguishing our cases of myelolipoma from liposarcoma.
Several theories exist as to the pathogenesis of these lesions. Foci of
extramedullary hematopoiesis during embryonic development which
becomes neoplastic through various stimulatory circumstances has
been speculated [15]; this theory would make the spleen an ideal
place for a myelolipoma, but unlike extramedullary hematopoiesis,
EAML is exceedingly rare in the spleen. There also appears to be synergy
between ML the adrenal cortex in that even ectopic adrenal cortex has
supported the growth of a myelolipoma [16]. It is thought that adrenal
cortical hyperplasia acts to upregulate the hematopoietic cells found
within the lesion [16].
Rare chromosomal abnormalities [17] and non-random X chromo-
some inactivation [1] have been documented in adrenal ML supporting
the neoplastic nature of myelolipoma. Bishop et al. documented the
same X-chromosomal inactivation pattern in both the fat and hemato-
poietic elements, suggesting they are derived from a common pluripo-
tent stem cell. No such ﬁndings have been reported in splenic EAML
most likely owing to its rarity in the spleen. Analysis of the MEN-1
gene does not show abnormalities as in other adenomatous orlogy Size Additional
features
onstrated a well demarcated
geneous splenic mass
13.9X11.6 cm thought to be a
rcoma
Spleen: 17X14.5X12.5 cm.
Mass: 14.3X12.0X11.5 cm
intrasplenic encapsulated
(ﬁbrous capsule) mass
onstrated centrally located
c mass measuring 8X6.8 cm. CT
s earlier demonstrated a 4.7 cm
in the same location
Spleen: 380 g; 15X13X7
Mass: well circumscribed
10X10X7 cm.
Spleen: 350 g. 12X11X9 cm
Mass: 8X6 cm rounded well
circumscribed, not
encapsulated, surrounded by
“ﬁbrous” bands
EMH and
congestion
outside the mass
in uninvolved
red pulp
ound showed a “rounded
-like mass:”
Spleen: 420 g. 12X10X6 cm.
Mass: no dimensions given;
rounded, well circumscribed
not encapsulated, surrounded
by “ﬁbrous” bands
EMH and
congestion
outside the mass
in uninvolved
red pulp
homogeneous, encapsulated
peritoneal” mass containing
of fat
Spleen: “Massively enlarged”
Mass: 17X15X10 cm,
encapsulated
Ectopic adrenal
tissue was
present in the
mass.
ing studies” showed a 4.2 cm
in the right ascending colon and
mass in the spleen
Spleen: 228 g.
Mass: Well circumscribed
mass 8.5 cm in greatest
dimension
onstrated a large splenic mass
cing the kidney.
Spleen: 197 g
Mass: Well deﬁned; No
dimension given.
puterized tomography; EMH = extra-medullary hematopoiesis; Pt = patient; NR = not
11N.S. Aguilera, A. Auerbach / Human Pathology: Case Reports 6 (2016) 8–12malignant adrenocortical tumors [18]. Although the above ﬁnding sup-
port ML as neoplastic the exact nature of the neoplasm is illusive, the
rarity of splenic EAML makes study difﬁcult.
In summary ML is a benign tumor-like mass that resembles bone
marrow and consists of hematopoietic elements and mature fat. Most
cases involve the adrenal glands, where it is thought that adrenal cortex
is synergistic with ML. EAML is known to occur in lung, liver,
retroperitoneum, mediastinum and testes. Splenic EAML are well de-
scribed in some animals, but are exceedingly rare in humans. In this
paper, we present two cases of splenic EAML in humans to further
study the entity and verify its existence. EAML are usually incidental
and require no speciﬁc treatment. Splenic ML must be differentiated
from extramedullary hematopoiesis, myeloid sarcoma, lipoma and
well differentiated liposarcoma.
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